Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Novogen — Rodman & Renshaw 18th Annual Global Investment Conference (September 2016)
13 slides from Kazia Therapeutics's conference presentation, Sep 12, 2016
Slide 1: Novogen Limited Presentation to Rodman & Renshaw 18th Annual Global Investment Conference
Novogen Limited Presentation to Rodman & Renshaw 18th Annual Global Investment Conference Dr James Garner New York, NY Chief Executive Officer 12 September 2016 [email protected] Version 2.4
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements ” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Novogen is a biotech company dedicated to driving sustainable, long-term growth in shareholder value
Novogen is a biotech company dedicated to driving sustainable, long-term growth in shareholder value Focus on unmet medical need Pipeline of novel therapies, targeting oncology patients poorly served by existing treatment options Clinical stage Lead molecule entering phase I in Q4 2016, with substan
Slide 4: Novogen is listed on ASX and NASDAQ (via ADRs) and is well-funded for current operations
Novogen is listed on ASX and NASDAQ (via ADRs) and is well-funded for current operations Market Capitalisation 0.00 0.50 1.00 1.50 2.00 2.50 3.00 NVGN NASDAQ Biotech Index US$ 31 million Shares on Issue 430 million (40% US, 60% Australia) Cash at Bank US$ 25 million Listing ASX: NRT NASDAQ: NVGN (1:
Slide 5: Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations
Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations Assets from internal discovery engines Programs taken through preclinical and clinical development, generally to completion of phase II Molecules partnered with pharma / large biotech for phase III develop
Slide 6: Novogen is configured for efficient and effective drug development
Novogen is configured for efficient and effective drug development 2015 2016 Early-stage, discovery-focused biotech with mixed portfolio of projects and limited clarity in path to value generation Clinical-stage, development-focused biotech, dedicated to oncology, and highly focused on value generat
Slide 7: Novogen anticipates a rich news flow of value-driving events over the next 12-18 months
Novogen anticipates a rich news flow of value-driving events over the next 12-18 months 1Q 2016 Granting of patent for SBP technology ü 2Q 2016 Granting of patent for ATM technology ü 3Q 2016 Submission of IND for Cantrixil ü 4Q 2016 Start of phase I trial for Cantrixil 2017 Submission of IND for An
Slide 8: Novogen has a strong management team with international experience in big pharma
7 Novogen has a strong management team with international experience in big pharma Dr James Garner Chief Executive Officer & Managing Director Physician / MBA; Extensive pharma drug development experience Dr David Brown Chief Scientific Officer Twenty years of drug discovery and development experien
Slide 9: Novogen's pipeline includes three molecules, with two entering the clinic over next nine months
Novogen’s pipeline includes three molecules, with two entering the clinic over next nine months Lead Optimisation Preclinical Proof-of-Concept IND-Enabling Tox & CMC Phase I Clinical Trials Phase II Clinical Trials Patent Expiry SBP TRXE-002-1 2035 SBP TRXE-009 2035 ATM ATM-3507 2035 ATM Platform Fi
Slide 10: Cantrixil (TRXE-002-1)
Cantrixil™ (TRXE-002-1) First-in-class agent that degrades the ‘tumor-initiating cells’ thought responsible for tumor recurrence after chemotherapy Single agent activity in PDX models of ovarian cancer Most chemotherapy agents considered more active against rapidly-dividing tumor cells, but less act
Slide 11: Cantrixil is entering a phase I clinical trial in 4Q 2016 in ovarian cancer
Cantrixil is entering a phase I clinical trial in 4Q 2016 in ovarian cancer Source: GLOBOCAN; Holschneider & Berek (2000), Sem Surg Onc 19(1):3-10; Decision Resources High Incidence Poor Prognosis with Existing Therapies Growing and Evolving Market Ovarian Cancer 17th most common tumour worldwide 7t
Slide 12: Anisina (ATM-3507)
Anisina™ (ATM-3507) First-in-class agent that targets microfilaments, thereby enhancing activity of microtubule-targeting chemotherapy Preclinical evidence of synergy with chemo Cancer cell cytoskeleton has two main components: microtubules and microfilaments. Microtubules are well-established targe
Slide 13: Slide 13
Novogen — Rodman & Renshaw 18th Annual Global Investment Conference (September 2016) on 6ix